

Public Declaration of Interests and Confidentiality Undertaking of Swissmedic Medicines Expert Committee Members

This document is aligned to the 'Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA) Scientific Committee members and experts' of the EMA.

SECTION 1: PERSONAL DETAILS

First Name Huldrych

Last Name Günthard

Organisation / Company University Hospital Zurich

Country of Organisation /
Company Switzerland

Committee

I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below.

Please specify the interests that you currently have (at the time of completion of the form) or have had within the past 5 years.

SECTION 2: PUBLIC DECLARATION OF INTERESTS

2.1 Employment

☒ No ☐ Yes

Please indicate if you are employed / have been employed, either full or part time, either as paid or unpaid employee in pharmaceutical company.

Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

2.2 Consultancy

☐ No ☒ Yes

Choose "Yes" if there is any activity in which you provide or have provided advice or services regardless as to whether or not you received a fee for this activity. Please indicate all of them below.

Provision of advice or services to a pharmaceutical company (in a particular field such as the development of a product) regardless of contractual arrangements or any form of remuneration. (Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product)

Note: Conference / Seminar attendance is not considered as consultancy but should be indicated under Financial Interests, if subject to a fee / honoraria.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
01/2018 - 12/2018	Merck	Islatravir, Doravirine	antiretroviral drug (NRTTI), HIV-treatment	
04/2020 - 12/2022	Gilead Sciences	Remdesivir	SARS-CoV-2	
01/2018 - TODAY	Gilead Sciences	TAF/FTC, Bictegravir, Lenacapravir	antiretroviral treatment (HIV)	
01/2019 - TODAY	ViiV Healthcare	Cabotegravir / Rilpivirene	Long-acting injectable antiretroviral therapy	
03/2022 - 12/2022	Jansen Vaccine	J and J vaccine (cAdvector based) (was never approved by Swissmedic in Switzerland)	Not approved in Switzerland	
03/2022 - 12/2022	Novartis	Ensovibep	SARS-CoV-2 drug developed by Molecular Partners, Zurich and licensed in by Novartis for potential development as an anti-SARS-CoV-2 drug	
11/2021 - 12/2021	Johnson and Johnson		Discussion on how the company could present itself on social media.	
01/2018 - TODAY	Merck / MSD	Islatravir	Antiretroviral Treatment, Member of Data Monitoring Committee (DMC)	

2.3 Strategic Advisory Role☒ No ☐ Yes

Choose "Yes" if you are participating or have participated in a (Scientific) Advisory Board/Steering Committee of a pharmaceutical company (e.g. board membership / directorship), with a right to vote on / influence the outcome of that body.

Participation (with a right to vote on/influence the outputs) in a (Scientific) Advisory Board/Steering Committee with the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Note: Involvement in Data Safety Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.6 Principal Investigator. Involvement in clinical research should be listed under section 2.6 Principal Investigator or 2.7 Investigator as appropriate.

2.4 Current Financial Interests

☒ No ☐ Yes

Choose "Yes" if you have any financial interests currently held in a pharmaceutical company.

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pension. Compensation, fees, honoraria, salaries currently being paid directly to you by a pharmaceutical company, other than payment for expenses incurred with research work or re-imbursement of reasonable expenses incurred in relation to conference/seminar attendance (i.e. accommodation and travel costs).

Current is interpreted at time of completion of this form.

2.5 Patent

☒ No ☐ Yes

Choose "Yes" if any patent for a medicinal / competitor product is currently owned by either yourself or your institution and you are a beneficiary.

Current is interpreted at time of completion of this form.

2.6 Principal Investigator

☒ No ☐ Yes

Choose "Yes" if there are trials for which you are acting or have acted as Principal Investigator

Principal Investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre trial or the leading investigator of a monocentre trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial. Involvement in Data Safety Monitoring Committee should be included in this section.

2.7 Investigator

☐ No ☒ Yes

Choose "Yes" if there are trials for which you are acting or have acted as Investigator.

Investigator involved in a clinical trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
03/2020 - 12/2021	Gilead Sciences	Remdesivir	SARS-CoV-2	yes
10/2021 - 12/2022	Roche	RO7496998 (Morning Sky Study)	Sars-CoV-2	yes
07/2021 - 12/2022	Roche	Meadow Spring Study=Follow up study to (Morning Sky Study)	oberservational study of RO7496998	yes

2.8 Grant / Funding to organisation/institution

☐ No ☒ Yes

Choose "Yes" if any grants or other funding is currently received by your institutional unit from a pharmaceutical company and you receive no personal gain; or where your Organisation (e.g. Patient Organisation) receives a grant or other funding from a pharmaceutical company and you (irrespective if you are employed by the Organisation or are a volunteer) receive no personal gain.

Refers to a grant or other funding from a pharmaceutical company, currently being received (as far as the individual is aware) by an institution (please indicate funding to the smallest institutional unit) or an organisation (e.g. patient organisation), irrespective of whether or not the individual is employed or is a volunteer, and the individual receives no personal gain.

X

Name of Pharmaceutical Company	Gilead Sciences
Subject Matter	Unrestricted research grant (not product related) on "HIV cure". I was a co-investigator on this grant. This was a competitive research program by Gilead on a global scale. The principle investigator was Prof. Alexandra Trkola, Institute of Medical Virology, University of Zurich
Amount of Money (CHF)	1'400'000
Funding paid into an institutional account with shared power of disposition?	yes

X

Name of Pharmaceutical Company	Gilead Sciences
Subject Matter	Unrestricted COVID-19 Grant (not product related). Competitive global grant program by Gilead Sciences
Amount of Money (CHF)	290'000
Funding paid into an institutional account with shared power of disposition?	yes

2.9 Any other interests or facts☒ No ☐ Yes

Choose "Yes" if further to the interest declared above you have any other interests or facts that should be made known to Swissmedic, the Swiss Agency of Therapeutic Products and the public.

By choosing "No" you declare on your honour that you do not have any other interests or facts to declare accordingly.